Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pembrolizumab vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer
To compare Progression Free Survival (PFS) per RECIST 1.1 by central imaging vendor in subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with pembrolizumab versus SOC chemotherapies.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or un...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation
1.To evaluate the comparative bioavailability of the MK-1439 100 mg adult formulation tablets under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated and coated granules, 0....
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A study to evaluate the safety, tolerability and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are already taking Metformin (licensed drug)
- After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared to placebo on A1C. - To assess the safety and tolerability of MK-3102.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Ragweed Efficacy and Safety Pediatric Trial
To evaluate the efficacy of MK-3641 sublingual immunotherapy tablet (12 Amb a 1-U) versus placebo in the treatment of children 5 to 17 years of age with ragweed-induced rhinoconjunctivitis, with or wi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Study in Postmenopausal Women with Osteoporosis
To evaluate the effect of treatment on BMD percent change from baseline at the femoral neck site assessed by DXA compared to placebo at the end of 24 months.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Study to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol
1. To assess the contraceptive efficacy of the ENG-E2 vaginal ring in women 18 and 35 years of age based on the number of in treatment pregnancies as expressed by the Pearl Index (PI) in the restricte...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in HCV GT1 or GT3 DAA Failures
(1)To evaluate the efficacy of the combination regimen of MK-5172, MK-3682 and MK-8408 with or without ribavirin as assessed by the proportion of subjects in each arm achieving SVR12 (Sustained Virolo...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical research study of 28 weeks to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept. 28 hetes, 3. fázisú, randomizált, aktív komparátor és placebo kontrollos, párhuzamos elrendezésű vizsgálat a subcutan alkalmazású SCH 900222/MK-3222 hatásosságának és biztonságosságának/tolerálhatóságának a felmérésére, amelyet opcionális, a hosszú távú biztonságosságot érintő, kiterjesztett vizsgálat követ, középsúlyos-súlyos, krónikus, plakk típusú pikkelysömörben szenvedő betegeknél
Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A
Update Il y a 5 ans
A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence
Evaluate efficacy of MK-0594 in maintaining absence of heavy alcohol drinking over Weeks 3-12 of a 12-week treatment period
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next